Summary & Overview
HCPCS G2072: Buprenorphine Implant MAT Weekly Bundle
HCPCS Level II code G2072 represents a weekly bundled medication-assisted treatment (MAT) service for buprenorphine implant insertion and removal provided by Medicare-enrolled opioid treatment programs. The bundle covers dispensing and/or administration of the implant, substance use counseling, individual and group therapy, and toxicology testing if performed. This code standardizes billing for integrated procedural and behavioral services tied to buprenorphine implant care.
Nationally, G2072 matters because it captures combined clinical and supportive services for patients receiving long-acting buprenorphine implants, aligning procedural care with psychosocial interventions and monitoring. Payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn how G2072 defines the service mix and site of care, which payers are relevant in comparative analyses, and what elements are typically included in the weekly bundle. The publication provides benchmarks and descriptive context for coding and billing practice, summarizes policy and coverage considerations that affect MAT delivery, and outlines clinical context for providers and administrators managing buprenorphine implant programs. Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Billing Code Overview
HCPCS Level II code G2072 describes medication assisted treatment with buprenorphine involving implant insertion and removal provided as a weekly bundled service. The bundle includes dispensing and/or administration of medication, substance use counseling, individual and group therapy, and toxicology testing if performed when the services are provided by a Medicare-enrolled opioid treatment program.
Service type: Medication-assisted treatment (MAT) bundle for buprenorphine implant insertion and removal.
Typical site of service: Opioid treatment program (clinic-based outpatient setting) enrolled in Medicare.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with moderate-to-severe opioid use disorder presents to a Medicare-enrolled opioid treatment program for a scheduled outpatient buprenorphine implant insertion and initial stabilization bundle. The multidisciplinary visit includes device insertion performed by an implant-trained physician under local anesthesia, dispensing and administration of the implant, substance use counseling, individual or group therapy sessions during the first week, and urine toxicology testing when performed. Typical workflow: pre-procedure nursing assessment and informed consent, baseline vitals and urine toxicology, procedure room insertion of the buprenorphine implant, post-procedure observation and discharge instructions, scheduled follow-up counseling and behavioral therapy visits within the weekly bundle period, documentation of medication dispensing and any toxicology results, and coordination with the clinic’s counselors and case managers for ongoing treatment adherence and safety monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources exceed typical for implant insertion (extensive intraoperative complications documented). |
23 |